Bristol-Myers Squibb Company (NYSE:BMY) announced that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor. Bristol-Myers Squibb Co (NYSE:BMY) shares after opening at $49.77 moved to $50.89 on last trade day and at the end of the day closed at $50.28. Company price to sales ratio in past twelve months was calculated as 5.08 and price to cash ratio as 18.41. Bristol-Myers Squibb Co (NYSE:BMY) showed a negative weekly performance of -2.54%.
GT Advanced Technologies (NASDAQ:GTAT) announced that it has received $58.6 million in orders this quarter for high temperature refractory metal furnaces that are used for a variety of industrial purposes. These orders will be reflected in Q2 reportable backlog and GT expects to recognize revenue from these orders during the second half of 2014. GT Advanced Technologies Inc. (NASDAQ:GTAT) shares fell -2.78% in last trading session and ended the day on $16.43. GTAT return on equity ratio is recorded as -33.60% and its return on assets is -9.30%. GT Advanced Technologies Inc. (NASDAQ:GTAT) yearly performance is 391.92%.
Analysts at Evercore Partners downgraded shares of Alaska Air Group, Inc. (NYSE:ALK) from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, April 1st. Alaska Air Group, Inc. (NYSE:ALK) shares moved down -2.72% in last trading session and was closed at $89.82, while trading in range of $88.95 – $93.30. Alaska Air Group, Inc. (NYSE:ALK) year to date (YTD) performance is 22.81%.
Vocus Inc. (NASDAQ:VOCS) a maker of cloud-based software for marketing and public relations, said it would be bought by private equity firm GTCR Valor Merger Sub Inc. for about $447 million. Vocus, Inc. (NASDAQ:VOCS) weekly performance is 34.43%. On last trading day company shares ended up $17.92. Vocus, Inc. (NASDAQ:VOCS) distance from 50-day simple moving average (SMA50) is 37.07%. Analysts mean target price for the company is $14.00.